# Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

> **NCT03056339** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 49 (actual)

## Conditions studied

- B-Lymphoid Malignancies
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Non-hodgkin Lymphoma

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Mesna
- **BIOLOGICAL:** iC9/CAR.19/IL15-Transduced CB-NK Cells
- **DRUG:** AP1903

## Key facts

- **NCT ID:** NCT03056339
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-21
- **Primary completion:** 2023-03-06
- **Final completion:** 2023-03-06
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2024-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03056339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03056339, "Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03056339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*